Bulk Manufacturer of Controlled Substances Application: Cambrex Charles City, 51642-51643 [2017-24201]
Download as PDF
<![CDATA[
51642
Federal Register / Vol. 82, No. 214 / Tuesday, November 7, 2017 / Notices
INTERNATIONAL TRADE
COMMISSION
[Investigation Nos. 701–TA–442 and 731–
TA–1095–1096 (Second Review)]
Lined Paper School Supplies From
China and India; Amended Schedule
for Expedited Reviews
United States International
Trade Commission.
ACTION: Notice.
AGENCY:
DATES:
October 27, 2017.
FOR FURTHER INFORMATION CONTACT:
Calvin Chang (202–205–3062), Office of
Investigations, U.S. International Trade
Commission, 500 E Street SW.,
Washington, DC 20436. Hearingimpaired persons can obtain
information on this matter by contacting
the Commission’s TDD terminal on 202–
205–1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202–205–2000.
General information concerning the
Commission may also be obtained by
accessing its internet server (https://
www.usitc.gov). The public record for
this investigation may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov.
SUPPLEMENTARY INFORMATION: On
October 6, 2017, the Commission
established a schedule for conducting
expedited reviews on lined paper school
supplies from China and India. On
October 26, 2017, the schedule was
published in the Federal Register (82
FR 49659). This notice corrects several
dates in the previously-published
schedule. In particular, the staff report
containing information concerning the
subject matter of the review will be
placed in the nonpublic record on
January 3, 2018 and made available to
persons on the Administrative
Protective Order service list for this
review. Comments pursuant to section
207.62(d) of the Commission’s rules are
due on or before January 9, 2018.
The Commission has determined that
these reviews are extraordinarily
complicated and therefore has
determined to exercise its authority to
extend the review period by up to 90
days pursuant to 19 U.S.C.
1675(c)(5)(B).
For further information concerning
these investigations see the
Commission’s notice cited above.
Authority: These investigations are being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to section 207.21 of the
Commission’s rules.
By order of the Commission.
Issued: November 1, 2017.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2017–24174 Filed 11–6–17; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Cambrex
Charles City
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with on or before January 8,
2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. Comments and requests for
hearings on applications to import raw
material are not appropriate. 72 FR 3417
(January 25, 2007).
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on June
12, 2017, Cambrex Charles City, 1205
11th Street, Charles City, Iowa 50616
applied to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
DATES:
ethrower on DSK3G9T082PROD with NOTICES
Controlled substance
Drug code
Gamma Hydroxybutyric Acid ...........................................................................................................................................
Amphetamine ...................................................................................................................................................................
Lisdexamfetamine ............................................................................................................................................................
Methylphenidate ..............................................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) .....................................................................................................................
Phenylacetone .................................................................................................................................................................
Cocaine ............................................................................................................................................................................
Codeine ...........................................................................................................................................................................
Oxycodone .......................................................................................................................................................................
Hydromorphone ...............................................................................................................................................................
Hydrocodone ...................................................................................................................................................................
Morphine ..........................................................................................................................................................................
Oripavine .........................................................................................................................................................................
Thebaine ..........................................................................................................................................................................
Opium extracts ................................................................................................................................................................
Opium fluid extract ..........................................................................................................................................................
Opium tincture .................................................................................................................................................................
Opium, powdered ............................................................................................................................................................
Oxymorphone ..................................................................................................................................................................
Noroxymorphone .............................................................................................................................................................
Fentanyl ...........................................................................................................................................................................
VerDate Sep<11>2014
17:29 Nov 06, 2017
Jkt 244001
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
E:\FR\FM\07NON1.SGM
07NON1
2010
1100
1205
1724
8333
8501
9041
9050
9143
9150
9193
9300
9330
9333
9610
9620
9630
9639
9652
9668
9801
Schedule
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Federal Register / Vol. 82, No. 214 / Tuesday, November 7, 2017 / Notices
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers, for dosage form
development, for clinical trials, and for
use in stability qualification studies.
Dated: October 30, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017–24201 Filed 11–6–17; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[OMB Number 1110–0060]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Revision of a
Currently Approved Collection—CJIS
Name Check Form (1–791)
Criminal Justice Information
Services Division, Federal Bureau of
Investigation, Department of Justice.
ACTION: 60-Day notice.
AGENCY:
The Department of Justice
(DOJ), Federal Bureau of Investigation
(FBI), Criminal Justice Information
Services (CJIS) Division, will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
The proposed information collection is
published to obtain comments from the
public and affected agencies.
DATES: Comments are encouraged and
will be accepted for 60 days until
January 8, 2018.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Gerry Lynn Brovey, Supervisory
Information Liaison Specialist, FBI,
CJIS, Resources Management Section,
Administrative Unit, Module C–2, 1000
Custer Hollow Road, Clarksburg, West
Virginia 26306 (facsimile: 304–625–
5093) or email glbrovey@ic.fbi.gov.
Written comments and/or suggestions
can also be sent to the Office of
Management and Budget, Office of
Information and Regulatory Affairs,
Attention Department of Justice Desk
Officer, Washington, DC 20503.
Additionally, comments may be
submitted via email to OIRA_
submission@omb.eop.gov.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
ethrower on DSK3G9T082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:29 Nov 06, 2017
Jkt 244001
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the Bureau of Justice
Statistics, including whether the
information will have practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of this information
collection:
(1) Type of Information Collection:
Revision of a currently approved
collection in use without an OMB
control number.
(2) The Title of the Form/Collection:
CJIS Name Check Request.
(3) The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
1–791.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract:
Primary: Agencies authorized to
submit applicant fingerprints into the
Next Generation Identification (NGI)
system for noncriminal justice purposes
such as employment, benefits, and
licensing. This form is completed to
obtain a name check for an applicant
when the fingerprints have been
rejected twice for quality to ensure
eligible individuals are not denied
employment, benefits, or licensing.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: It is estimated that 77,816
respondents will complete each form
within approximately 5 minutes.
(6) An estimate of the total public
burden (in hours) associated with the
collection: There are an estimated 6,485
total annual burden hours associated
with this collection.
If additional information is required
contact: Melody Braswell, Department
Clearance Officer, United States
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
51643
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE., 3E.405A,
Washington, DC 20530.
Dated: November 2, 2017.
Melody Braswell,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2017–24208 Filed 11–6–17; 8:45 am]
BILLING CODE 4410–02–P
DEPARTMENT OF JUSTICE
Notice of Lodging of Proposed
Consent Decree Under the Clean Air
Act
On October 31, 2017, the Department
of Justice lodged a proposed consent
decree with the United States District
Court for the Southern District of Texas
in the lawsuit entitled United States and
the Louisiana Department of
Environmental Quality v. Exxon Mobil
Corp. and ExxonMobil Oil Corp., Civil
Action No. 4:17-cv-03302.
The United States and Louisiana
Department of Environmental Quality
filed this lawsuit under the Clean Air
Act and Louisiana Environmental
Quality Act. The complaint seeks
injunctive relief and civil penalties
based on violations of the Clean Air
Act’s New Source Review requirements,
New Source Performance Standards,
National Emissions Standards for
Hazardous Air Pollutants, ‘‘Title V’’
program requirements and operating
permits, and related Texas and
Louisiana state implementation plan
requirements. The alleged violations
involve flares used at petrochemical
manufacturing plants owned and
operated by the defendants, Exxon
Mobil Corp. and ExxonMobil Oil Corp.,
in Baytown and Beaumont, Texas, and
Baton Rouge, Louisiana. The consent
decree requires the defendants to
perform injunctive relief, pay a
$2,500,000 civil penalty, perform a
Supplemental Environmental Project in
Baytown, Texas, and two Beneficial
Environmental Projects in Louisiana.
The publication of this notice opens
a period for public comment on the
proposed consent decree. Comments
should be addressed to the Assistant
Attorney General, Environment and
Natural Resources Division, and should
refer to United States and the Louisiana
Department of Environmental Quality v.
Exxon Mobil Corp. and ExxonMobil Oil
Corp., D.J. Ref. No. 90–5–2–1–10128. All
comments must be submitted no later
than thirty (30) days after the
publication date of this notice.
E:\FR\FM\07NON1.SGM
07NON1
]]>Agencies
[Federal Register Volume 82, Number 214 (Tuesday, November 7, 2017)]
[Notices]
[Pages 51642-51643]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-24201]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Cambrex
Charles City
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with on or before
January 8, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152. Comments and
requests for hearings on applications to import raw material are not
appropriate. 72 FR 3417 (January 25, 2007).
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on June
12, 2017, Cambrex Charles City, 1205 11th Street, Charles City, Iowa
50616 applied to be registered as a bulk manufacturer of the following
basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid.......... 2010 I
Amphetamine........................ 1100 II
Lisdexamfetamine................... 1205 II
Methylphenidate.................... 1724 II
4-Anilino-N-phenethyl-4-piperidine 8333 II
(ANPP).
Phenylacetone...................... 8501 II
Cocaine............................ 9041 II
Codeine............................ 9050 II
Oxycodone.......................... 9143 II
Hydromorphone...................... 9150 II
Hydrocodone........................ 9193 II
Morphine........................... 9300 II
Oripavine.......................... 9330 II
Thebaine........................... 9333 II
Opium extracts..................... 9610 II
Opium fluid extract................ 9620 II
Opium tincture..................... 9630 II
Opium, powdered.................... 9639 II
Oxymorphone........................ 9652 II
Noroxymorphone..................... 9668 II
Fentanyl........................... 9801 II
------------------------------------------------------------------------
[[Page 51643]]
The company plans to manufacture the listed controlled substances
in bulk for sale to its customers, for dosage form development, for
clinical trials, and for use in stability qualification studies.
Dated: October 30, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017-24201 Filed 11-6-17; 8:45 am]
BILLING CODE 4410-09-P
